[{"id":"083867de-5a50-4a67-ac63-c11e42dc2513","acronym":"","url":"https://clinicaltrials.gov/study/NCT05432401","created_at":"2022-06-27T14:54:11.243Z","updated_at":"2024-07-02T16:36:08.274Z","phase":"Phase 1","brief_title":"TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05432401","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" FLT3 • IL6","pipe":" | ","alterations":" FLT3 expression • FLT3 positive","tags":["FLT3 • IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 expression • FLT3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA05"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 06/09/2023","primary_completion_date":" 06/09/2023","study_txt":" Completion: 06/09/2025","study_completion_date":" 06/09/2025","last_update_posted":"2022-06-27"}]